Warburg and Advent in the lead to acquire Baxter's biopharma unit - Reuters News Agency
Business & FinanceDeals

Warburg and Advent in the lead to acquire Baxter’s biopharma unit

Reuters was first to report on Sunday that a private equity consortium comprising Warburg Pincus and Advent International was in advanced talks to acquire medical device maker Baxter International Inc’s BAX.N biopharma solutions business in a deal that could exceed $4 billion. Warburg Pincus and Advent submitted the most attractive offer to Baxter in an auction that drew interest from other private equity firms as well as major players in the biomedical sector such as Thermo Fisher Scientific Inc. The Reuters scoop has since been confirmed by Baxter.

Market Impact

The deal could reach or exceed $4 billion. 

Article Tags
Topics of Interest: Business & FinanceDeals
Type: Reuters Best
Sectors: Business & Finance
Regions: Americas
Countries: United States
Win Types: Speed
Story Types: Exclusive / Scoop
Media Types: Text
Customer Impact: Significant National Story
In this photo illustration Baxter International Inc. logo seen displayed on a smartphone. (Photo by Igor Golovniov / SOPA Images/Sipa USA)No Use Germany.
Sign up for email updates
Sign up for email updates